Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Sell
37
BIVI Quote, Financials, Valuation and Earnings
Last price:
$1.16
Seasonality move
:
75.55%
Day range:
$1.08 - $1.22
52-week range:
$0.62 - $7.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.89x
Volume:
516.6K
Avg. volume:
557.3K
1-year change:
-76.15%
Market cap:
$21.4M
Revenue:
--
EPS (TTM):
-$3.46
Analysts' Opinion
-
Consensus RatingBioVie has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.50, BioVie has an estimated upside of 374.14% from its current price of $1.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $1.16.
Fair Value
-
According to the consensus of 2 analysts, BioVie has 374.14% upside to fair value with a price target of $5.50 per share.
BIVI vs. S&P 500
-
Over the past 5 trading days, BioVie has overperformed the S&P 500 by 40.01% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioVie does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioVie has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BioVie reported revenues of --.
Earnings Growth
-
BioVie has grown year-over-year earnings for 0 quarters straight. In the most recent quarter BioVie reported earnings per share of -$0.46.
Enterprise value:
-3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$35.4M | -$44.4M | -$23.9M | -$8.8M | -$7.3M | |
| EBITDA | -$37M | -$39M | -$22.7M | -$7.5M | -$7M | |
| Diluted EPS | -$14.90 | -$11.69 | -$3.46 | -$2.20 | -$0.46 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.9M | $30.5M | $46M | $20.6M | $24.7M | |
| Total Assets | $13.5M | $31.9M | $47.2M | $21.5M | $25.7M | |
| Current Liabilities | $322.4K | $4.4M | $7.8M | $14M | $1.5M | |
| Total Liabilities | $384.9K | $15.8M | $21.1M | $14M | $1.8M | |
| Total Equity | $13.1M | $16.1M | $26.1M | $7.5M | $23.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$29M | -$41.1M | -$22M | -$5.9M | -$8.6M | |
| Cash From Investing | -- | $223.9K | -- | -- | -- | |
| Cash From Financing | $44.3M | $15.4M | $26.2M | $4.9M | $13M | |
| Free Cash Flow | -$29M | -$41.1M | -$22M | -$5.9M | -$8.6M | |
BIVI
Sector
Market Cap
$21.4M
$35.1M
Price % of 52-Week High
15.47%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-76.15%
-40.62%
Beta (5-Year)
1.180
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.96
200-day SMA
Sell
Level
$2.10
Bollinger Bands (100)
Sell
Level
0.94 - 2.1
Chaikin Money Flow
Sell
Level
-149.4M
20-day SMA
Buy
Level
$0.87
Relative Strength Index (RSI14)
Buy
Level
61.99
ADX Line
Buy
Level
35.22
Williams %R
Neutral
Level
-28.0702
50-day SMA
Buy
Level
$1.00
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
235.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Stock Forecast FAQ
In the current month, BIVI has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BIVI average analyst price target in the past 3 months is $5.50.
-
Where Will BioVie Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioVie share price will rise to $5.50 per share over the next 12 months.
-
What Do Analysts Say About BioVie?
Analysts are divided on their view about BioVie share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioVie is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is BioVie's Price Target?
The price target for BioVie over the next 1-year time period is forecast to be $5.50 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BIVI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioVie is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BIVI?
You can purchase shares of BioVie via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioVie shares.
-
What Is The BioVie Share Price Today?
BioVie was last trading at $1.16 per share. This represents the most recent stock quote for BioVie. Yesterday, BioVie closed at $1.16 per share.
-
How To Buy BioVie Stock Online?
In order to purchase BioVie stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is up 34.66% over the past day.
Buy
63
SKX alert for May 7
Skechers USA [SKX] is down 0.07% over the past day.
